Trump to appeal tariff ruling, warns of economic consequences
CAMBRIDGE, MA—Justin B. Klee, Co-Chief Executive Officer of Amylyx Pharmaceuticals , Inc. (NASDAQ:AMLX), recently sold shares of the company’s common stock. According to a filing with the Securities and Exchange Commission, Klee sold a total of 21,490 shares on March 31, 2025, at a weighted average price of approximately $3.46 per share, amounting to a total transaction value of $74,454. The stock, which currently trades at $3.78 and has a market capitalization of about $296 million, is considered undervalued according to InvestingPro analysis. Analysts maintain a moderate buy rating on the stock, with price targets ranging from $3 to $12.
The sale was conducted to cover tax withholding obligations related to the vesting of restricted stock units, as noted in the filing. Following this transaction, Klee retains ownership of 3,355,276 shares in the company. The shares were sold automatically and not at Klee’s discretion, as clarified in the footnotes of the SEC filing. With a "FAIR" overall financial health score and year-to-date return of -11.64%, InvestingPro subscribers can access comprehensive insider trading analysis and over 30 additional key metrics for deeper investment insights.
In other recent news, Amylyx Pharmaceuticals Inc. has received clearance from the U.S. Food and Drug Administration (FDA) to resume its Phase 1 trial for AMX0114, a potential treatment for amyotrophic lateral sclerosis (ALS). This development allows the company to proceed with patient screening, enrollment, and dosing in the United States. The trial, named LUMINA, is designed as a multicenter, randomized, placebo-controlled study and will also commence in Canada this year. It aims to assess the safety and biological activity of AMX0114, involving approximately 48 individuals with ALS. The drug targets calpain-2, a protein associated with neurodegenerative processes, and the trial will monitor neurofilament light (NfL) levels, a biomarker for ALS. Amylyx anticipates sharing early cohort data from this trial within the year. Dr. Camille L. Bedrosian, the Chief Medical (TASE:BLWV) Officer of Amylyx, has highlighted the potential of AMX0114 based on preclinical efficacy studies. The company’s focus remains on developing treatments for diseases with significant unmet medical needs.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.